BioSpace News Archive

InMode Ltd., a leading global provider of innovative medical technologies, announced that InMode will present at the following investor conferences in November.

Blueprint Medicines (NASDAQ: BPMC) today announced its 2027 Blueprint to achieve precision medicine at scale, a five-year business strategy to expand the company’s reach to broader patient populations by leveraging its scientific leadership, proven development capability and integrated business.

Freenome announced 50 hospitals and community oncology practices across the United States have joined as clinical partners for its Vallania Study.

Intensity Therapeutics, Inc. today announced that three abstracts have been selected for presentation at key upcoming clinical oncology conferences.

Avilar Therapeutics today announced it will present preclinical data demonstrating the degradation of extracellular proteins using its asialoglycoprotein receptor (ASGPR) targeting chimeras (ATAC) platform at the Keystone Symposium on Targeted Protein Degradation being held in Vancouver, British Columbia, November 6-8, 2022.

Ecolab Third Quarter Reported Diluted EPS $1.21; Adjusted Diluted EPS $1.30 With Double-Digit Growth in Sales and Pricing.

CareDx, Inc. today announced the results of a new study published in the Clinical Journal of the American Society of Nephrology (CJASN)1 showing that CareDx’s AlloSure® Kidney donor-derived cell-free DNA (dd-cfDNA) solution identifies early signs of allograft rejection and BK virus infection in pediatric kidney transplant patients.

ABIOMED, Inc. today announces financial results for the quarter ended September 30, 2022.

Kala Pharmaceuticals, Inc. today announced the appointment of Marjan Farid, M.D., to its Board of Directors.

KemPharm, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, November 9, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the third quarter 2022.